Jefferies Financial Group Inc. Lowers Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Jefferies Financial Group Inc. lowered its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 12.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 47,500 shares of the biotechnology company's stock after selling 6,623 shares during the quarter. Jefferies Financial Group Inc. owned about 0.07% of Blueprint Medicines worth $4,143,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in shares of Blueprint Medicines in the 4th quarter worth $51,000. Headlands Technologies LLC purchased a new position in Blueprint Medicines during the fourth quarter worth about $65,000. Thematics Asset Management acquired a new stake in Blueprint Medicines in the fourth quarter valued at about $72,000. Covestor Ltd lifted its position in Blueprint Medicines by 62.7% in the fourth quarter. Covestor Ltd now owns 973 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 375 shares during the period. Finally, Asset Management One Co. Ltd. purchased a new stake in Blueprint Medicines in the 4th quarter valued at approximately $88,000.

Analyst Ratings Changes

Several analysts have recently commented on BPMC shares. Needham & Company LLC reduced their price target on Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating for the company in a report on Monday, April 28th. Wall Street Zen upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a research report on Friday, May 2nd. HC Wainwright restated a "buy" rating and set a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, May 2nd. JPMorgan Chase & Co. upped their price target on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Finally, Morgan Stanley started coverage on shares of Blueprint Medicines in a research note on Thursday, March 20th. They issued an "equal weight" rating and a $100.00 price objective for the company. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $126.56.

Blueprint Medicines Price Performance

Shares of BPMC traded down $1.91 during mid-day trading on Friday, reaching $101.15. 901,724 shares of the company's stock were exchanged, compared to its average volume of 787,830. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a 52-week low of $73.04 and a 52-week high of $121.90. The company has a market cap of $6.53 billion, a price-to-earnings ratio of -93.66 and a beta of 0.83. The company has a 50-day simple moving average of $91.51 and a two-hundred day simple moving average of $94.65.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). The company had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Blueprint Medicines's quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.40 EPS. On average, sell-side analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Insider Activity at Blueprint Medicines

In other news, Director Jeffrey W. Albers sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $101.14, for a total value of $505,700.00. Following the completion of the transaction, the director now owns 146,630 shares of the company's stock, valued at $14,830,158.20. The trade was a 3.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $100.51, for a total transaction of $228,559.74. Following the completion of the sale, the chief operating officer now directly owns 64,718 shares of the company's stock, valued at $6,504,806.18. The trade was a 3.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 17,777 shares of company stock valued at $1,762,190 over the last quarter. Insiders own 4.21% of the company's stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.